Replies to post #139731 on Biotech Values

[DewDiligence]

XenoPort intends to file an Investigational New Drug Application (IND) for XP23829 for the treatment of relapsing remitting MS with the U.S. Food and Drug Administration (FDA) in the second quarter of 2012 and expects to initiate human clinical trials later this year.

This likely places XP23829 about six years behind BG-12, where the NDA and MAA were recently submitted (#msg-72621306).